# Reistone Biopharma Company

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/reistone-biopharma-company

- Industry: Biotechnology
- Headquarters: Shanghai, China
- Website: www.reistonebio.com
- Total disclosed funding: $100M
- Latest round: Series A (May 9, 2022)
- Investors on record: 5

## About

Founded in 2018 and based in Shanghai, China, Reistone Biopharma Company Limited is a clinical-stage biopharmaceutical company focused on developing novel medicines for patients suffering from immuno-inflammatory disorders. In May 2022, Reistone Biopharma Company Limited raised approximately USD 100 million in Series A funding from Huagai Capital including Hanne Capital, Yinglian Health Industry Fund, Zero2IPO Ventures, and Zhangjiang Haoheng Capital. Min Wang Irwin is the CEO and co-founder of the company.

The company provides its core program SHR0302, a JAK1 inhibitor that is in phase III clinical trial after meeting endpoints in phase II studies in atopic dermatitis, ulcerative colitis, and alopecia areata. The firm's other products include SHR1459, an orally bioavailable, potent BTK inhibitor, as well as RS1805, a gut-selective RORgt inhibitor.

The organization plan to use the May 2022 funding to advance the R&D and global clinical development of its drug candidates for immuno-inflammatory diseases.

## Funding rounds

- Series A, May 9, 2022, $100M — Zero2IPO Ventures, Huagai Capital, Hanne Capital, Yinglian Health Industry Fund, Zhangjiang Haoheng Capital

## Investors

- Zero2IPO Ventures (https://capitalatlas.ai/funds/zero2ipo-ventures) — Series A
- Huagai Capital (https://capitalatlas.ai/funds/huagai-capital) — Series A
- Hanne Capital (https://capitalatlas.ai/funds/hanne-capital) — Series A
- Yinglian Health Industry Fund — Series A
- Zhangjiang Haoheng Capital (https://capitalatlas.ai/funds/zhangjiang-haoheng-capital) — Series A